Perphenazine–Macrocycle Conjugates Rapidly Sequester the Aβ42 Monomer and Prevent Formation of Toxic Oligomers and Amyloid

• Published in: ACS chemical neuroscience 2023-01, Vol.14 (1), p.87-98
• Main Authors: Ball, Sarah R., Adamson, Julius S. P., Sullivan, Michael A., Zimmermann, Manuela R., Lo, Victor, Sanz-Hernandez, Maximo, Jiang, Xiaofan, Kwan, Ann H., McKenzie, André D. J., Werry, Eryn L., Knowles, Tuomas P. J., Kassiou, Michael, Meisl, Georg, Todd, Matthew H., Rutledge, Peter J., Sunde, Margaret
• Format: Article
• Language: English
• Subjects: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloidogenic Proteins; Humans; Peptide Fragments; Perphenazine
• ISSN: 1948-7193; 1948-7193
• DOI: 10.1021/acschemneuro.2c00498

Alzheimer’s disease is imposing a growing social and economic burden worldwide, and effective therapies are urgently required. One possible approach to modulation of the disease outcome is to use small molecules to limit the conversion of monomeric amyloid (Aβ42) to cytotoxic amyloid oligomers and fibrils. We have synthesized modulators of amyloid assembly that are unlike others studied to date: these compounds act primarily by sequestering the Aβ42 monomer. We provide kinetic and nuclear magnetic resonance data showing that these perphenazine conjugates divert the Aβ42 monomer into amorphous aggregates that are not cytotoxic. Rapid monomer sequestration by the compounds reduces fibril assembly, even in the presence of pre-formed fibrillar seeds. The compounds are therefore also able to disrupt monomer-dependent secondary nucleation, the autocatalytic process that generates the majority of toxic oligomers. The inhibitors have a modular design that is easily varied, aiding future exploration and use of these tools to probe the impact of distinct Aβ42 species populated during amyloid assembly.